RNAI-Based Method of Screening and Characterizing Drug Combinations

In one aspect, the invention is directed to a method of characterizing a mechanism of action of a combination of agents. The method comprises contacting a plurality of populations of cells with a combination of agents to be assessed, wherein each population of cells have one gene of interest targeted by a small hairpin RNA (shRNA) and wherein the gene of interest regulates cell death and a plurality of genes that regulate cell death are targeted in the plurality of populations of cells. A responsiveness of each population of cells to the combination of agents is determined, thereby obtaining an shRNA signature of the combination of agents so as to identify one or more genes that mediate a response to the combination of agents, thereby characterizing the mechanism of action of the combination of agents. In another aspect, the invention is directed to a method of determining whether a patient population treated with a first agent would benefit from a treatment using the first agent in combination with one or more additional agents. In yet another aspect, the invention is directed to method of determining whether a formulation of one or more agents maintains a mechanism of action of the one or more agents when unformulated.

Researchers

Michael Hemann / Justin Pritchard / Douglas Lauffenburger

Departments: Department of Biology, Department of Biological Engineering
Technology Areas: Biotechnology: DNA & RNA Editing / Drug Discovery and Research Tools: Cell Interrogation, Genomics & Proteomics
Impact Areas: Healthy Living

  • rnai based method of screening and characterizing drug combinations
    United States of America | Granted | 9,670,486

License this technology

Interested in this technology? Connect with our experienced licensing team to initiate the process.

Sign up for technology updates

Sign up now to receive the latest updates on cutting-edge technologies and innovations.